Lakefront Biotherapeutics (LKFT) Cash & Current Investments (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Cash & Current Investments for 13 consecutive years, with $3.4 billion the latest figure, recorded in Q1 2026.

• Quarterly Cash & Current Investments fell 54.02% year-over-year to $3.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 billion (down 54.02% YoY) and the FY2025 annual result came in at $3.5 billion, down 53.5% from the prior year.
• Cash & Current Investments eased to $3.4 billion in Q1 2026 per LKFT's latest filing, from $3.4 billion in the prior quarter.
• Over the last five years, Cash & Current Investments for LKFT reached as high as $8.0 billion in Q1 2024 and fell as low as -$2.9 billion in Q3 2022.
• A 5-year average of $4.1 billion and a median of $4.2 billion in 2023 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments sank 61.71% — and 2025, when it soared 14552.36%.
• Year by year, Cash & Current Investments stood at $2.0 billion in 2022, then soared by 104.62% to $4.2 billion in 2023, then retreated by 15.39% to $3.5 billion in 2024, then retreated by 3.83% to $3.4 billion in 2025, then dropped by 0.53% to $3.4 billion in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $3.4 billion, $3.4 billion, and $7.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.